Mostrar el registro sencillo del ítem

dc.contributor.authorSelheim, Frode
dc.contributor.authorAasebø, Elise
dc.contributor.authorReikvam, Håkon
dc.contributor.authorBruserud, Øystein
dc.contributor.authorHernández Valladares, María del Carmen
dc.date.accessioned2025-03-21T11:51:09Z
dc.date.available2025-03-21T11:51:09Z
dc.date.issued2025-02-17
dc.identifier.citationSelheim, F.; Aasebø, E.; Reikvam, H.; Bruserud, Ø.; Hernandez-Valladares, M. Proteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34+ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/ Ferroptosis. Proteomes 2025, 13, 11. https://doi.org/10.3390/proteomes13010011es_ES
dc.identifier.urihttps://hdl.handle.net/10481/103223
dc.descriptionThis research was funded by Kreftforeningen, the Norwegian Cancer Society (grant no. 100933) and by the Research Council of Norway INFRASTRUKTUR-program (project no. 295910). Research Council of Norway.es_ES
dc.descriptionSupplementary Materials. The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/proteomes13010011/s1es_ES
dc.description.abstractAcute myeloid leukemia (AML) is an aggressive bone marrow malignancy that can be cured only by intensive chemotherapy possibly combined with allogeneic stem cell transplantation. We compared the pretreatment proteomic profiles of AML cells derived from 50 patients at the time of first diagnosis with normal CD34+ bone marrow cells. A comparison based on all AML and CD34+ normal cell populations identified 121 differentially abundant proteins that showed at least 2-fold differences, and these proteins included several markers of neutrophil differentiation (e.g., TLR2, the integrins ITGM and ITGX, and downstream mediators including RHO GTPase, S100A8, S100A9, S100A22). However, the expression of these 121 proteins varied between patients, and a subset of 28 patients was characterized by increased long-term AML-free survival, signs of myeloid AML cell differentiation, and favorable genetic abnormalities. These two main patient subsets (28 with differentiation versus 22 with fewer signs of differentiation) also differed with regard to the phosphorylation of 16 differentially abundant proteins. Furthermore, we also classified our patients based on their expression of 16 proteins involved in the regulation of iron metabolism/ferroptosis and showing differential expression when comparing AML cells and normal CD34+ cells. Among the 22 patients with less favorable prognosis, we could then identify a genetically heterogeneous subset characterized by adverse prognosis (i.e., death from primary resistance/relapse) and an iron metabolism/ferroptosis protein profile showing similarities with normal CD34+ cells. We conclude that proteomic profiles differ between AML and normal CD34+ cells; especially, proteomic differences reflecting differentiation and regulation of iron metabolism/ferroptosis are associated with risk of relapse after intensive conventional therapy.es_ES
dc.description.sponsorshipKreftforeningen, the Norwegian Cancer Society (100933)es_ES
dc.description.sponsorshipResearch Council of Norway INFRASTRUKTUR-program (295910)es_ES
dc.description.sponsorshipResearch Council of Norwayes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAcute myeloid leukemiaes_ES
dc.subjectNormal CD34+ bone marrow cellses_ES
dc.subjectHematopoiesis es_ES
dc.subjectDifferentiationes_ES
dc.subjectIntegrinses_ES
dc.titleProteomic Comparison of Acute Myeloid Leukemia Cells and Normal CD34+ Bone Marrow Cells: Studies of Leukemia Cell Differentiation and Regulation of Iron Metabolism/Ferroptosises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/proteomes13010011
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional